Corneal ring segments proving their worth

Article

Ferrara corneal rings are a useful tool in the treatment of keratoconus but long-term stability still needs to be established.

Ferrara corneal rings are a useful tool in the treatment of keratoconus but long-term stability still needs to be established, according to Akef El Maghraby and colleagues from the Magrabi Eye and Ear Center, Jeddah, Saudi Arabia.

In a prospective, non-comparative study, 100 corneas with keratoconus were implanted with Ferrara intracorneal ring segments. Uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), spherical equivalent, cylinder power, topographic average K readings and cylinder were measured preoperatively and at one week, one, three, six and nine months postoperatively.

By the first month, all parameters had improved significantly and 92% maintained or improved their BCVA. No case required explantation and neither cone nor the depth of the segments affected the outcomes. Results were stable through the duration of follow-up.

The results suggest that intracorneal ring segments are effective but more long-term follow-up is required to establish stability.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.